Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI South Africa ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.73 (market cap $4.49B), while iShares MSCI South Africa ETF trades at $61.61. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | EZA | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $81.60 |
52-Week Low | $20.06 | $52.86 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EZA trades at $64.63, up 0.98% on the day, but technical indicators signal a bearish trend with moving averages pointing lower. The stock faces resistance near $65 and has support at $63. A dividend of $1.43 is scheduled for payment on June 22, 2026. Recent news highlights South Africa's extended fuel tax cut, which may impact regional economic conditions relevant to the fund's holdings.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Risks include exposure to South African economic policies and commodity volatility. Investors should await updated financials for a clearer valuation picture, as current metrics are unavailable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
